SCHEMBL5075855

SCHEMBL5075855

O=C(O)c1c(O)c(O)c2c(c1O)C(=O)c1ccccc1C2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
MAPT P10636 6/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
TTR P02766 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
MAOA P21397 3/20 0.52
MAPK1 P28482 3/20 0.52
RECQL P46063 3/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP3A4 P08684 2/20 0.52
HPGD P15428 2/20 0.52
ALOX15 P16050 2/20 0.52
ALOX12 P18054 2/20 0.52
DAPK1 P53355 2/20 0.52
CYP1B1 Q16678 2/20 0.52
HSD17B10 Q99714 2/20 0.52
CYP1A1 P04798 1/20 0.52
HSPD1 P10809 1/20 0.52
ACHE P22303 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360530 1.00 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL9131211 0.92 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL28019688 0.92 MAPT (0.55) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL23198953 0.86 MAPT (0.53) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL8545502 0.86 MAPT (0.53) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL899150 0.83 MEN1 (0.68) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL23198957 0.80 HSD17B10 (0.58) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL6003260 0.79 MAPT (0.57) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL8581315 0.79 MEN1 (0.63) ALDH1A1MAPTKMT2AMEN1TTR
SCHEMBL6548219 0.79 BCL2 (0.67) ALDH1A1MAPTKMT2AMEN1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP claimed
EP-0498707-B1 Process of dyeing keratinous fibers with a mono- or di-hydroxyindole and a non-oxidative aromatic carbonyl derivative and dyeing agent OREAL (FR) 1995-08-02 EP claimed
EP-0498707-A1 Process of dyeing keratinous fibers with a mono- or di-hydroxyindole and a non-oxidative aromatic carbonyl derivative and dyeing agent L'OREAL (FR) 1992-08-12 EP claimed
US-5064442-A HAIR DYES L'OREAL (FR) 1991-11-12 US claimed
US-4602913-A Use of hydroxyanthraquinones for the coloration of human keratin fibres L'OREAL (FR) 1986-07-29 US claimed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP disclosed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US disclosed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP disclosed
US-20080207758-A1 Reaction product of rhein with bases or amino acids; antidiabetic agents; gastrointestinal disorders; antiarthritic agents CONG XIAODONG 2008-08-28 US disclosed
EP-0498707-B1 Process of dyeing keratinous fibers with a mono- or di-hydroxyindole and a non-oxidative aromatic carbonyl derivative and dyeing agent OREAL (FR) 1995-08-02 EP disclosed
US-5275626-A Hair dyes L'OREAL (FR) 1994-01-04 US disclosed
EP-0498707-A1 Process of dyeing keratinous fibers with a mono- or di-hydroxyindole and a non-oxidative aromatic carbonyl derivative and dyeing agent L'OREAL (FR) 1992-08-12 EP disclosed
US-5064442-A HAIR DYES L'OREAL (FR) 1991-11-12 US disclosed
US-4602913-A Use of hydroxyanthraquinones for the coloration of human keratin fibres L'OREAL (FR) 1986-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207758-A1 Reaction product of rhein with bases or amino acids; antidiabetic agents; gastrointestinal disorders; antiarthritic agents ARGLU1, RO60, CROCC ALDH1A1 3432/4885MAPT 3631/4885KMT2A 4354/4885
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 ALDH1A1 3685/4885MAPT 2071/4885KMT2A 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.